{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:51:53Z","timestamp":1781589113588,"version":"3.54.5"},"reference-count":34,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2026,6]]},"abstract":"ABSTRACT<\/jats:title>\n \n Purpose<\/jats:title>\n Janus kinase inhibitors (JAKi) are medicines used to treat inflammatory rheumatic musculoskeletal diseases (IRMDs) and inflammatory bowel diseases (IBDs). In Europe, JAKis received marketing authorisation in 2017 for rheumatoid arthritis. Subsequently, the European Medicines Agency (EMA) issued multiple safety alerts concerning this drug class. We aimed to examine how the use of JAKis developed in Finland.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a retrospective time series analysis on the initiations and use of JAKis in the treatment of IRMD and IBD, utilising the national medicines reimbursement registry 2018\u20132023, including nearly all JAKi prescriptions. We assessed the initiators' age, line of treatment and atherosclerotic risk factors.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Between 2018 and 2023, the prevalence of\n JAKi<\/jats:styled-content>\n use increased from 0.14 to 0.43\/1000 inhabitants, from 756 to 1740 among\n IRMD<\/jats:styled-content>\n patients and from 11 to 672 among\n IBD<\/jats:styled-content>\n patients. In\n IRMD<\/jats:styled-content>\n ,\n JAKis<\/jats:styled-content>\n were rapidly adopted with 677 initiations in 2018, declining to 328 initiations in 2023. The corresponding numbers in\n IBD<\/jats:styled-content>\n were 11 in 2018 and 358 in 2023. The mean age of\n IRMD<\/jats:styled-content>\n patients initiating\n JAKis<\/jats:styled-content>\n decreased from 54\u2009years in 2021 to 41\u2009years in 2023, while\n IBD<\/jats:styled-content>\n patients' mean age changed from 42 to 39\u2009years. In 2020, 52% of\n IRMD<\/jats:styled-content>\n Patients Initiated\n JAKi<\/jats:styled-content>\n in second\u2010line of treatment but by 2023, this decreased to 31%. Prevalence of atherosclerotic risk factors declined.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n The uptake of\n JAKis<\/jats:styled-content>\n among\n IRMD<\/jats:styled-content>\n patients were initially fast. After safety alerts, initiation rates declined and shifted towards younger patients with fewer atherosclerotic risk factors. In contrast, the uptake of\n JAKis<\/jats:styled-content>\n among\n IBD<\/jats:styled-content>\n patients increased steadily.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/pds.70389","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:04:56Z","timestamp":1779235496000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use Patterns of Novel Janus Kinase Inhibitors After the First Safety Alerts: A Nationwide Register\u2010Based Time Series Analysis"],"prefix":"10.1002","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0179-9478","authenticated-orcid":false,"given":"Jarno","family":"Rutanen","sequence":"first","affiliation":[{"name":"Faculty of Social Sciences Tampere University Tampere Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0287-9525","authenticated-orcid":false,"given":"Pekka","family":"Heino","sequence":"additional","affiliation":[{"name":"Research Unit Social Insurance Institution of Finland Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1300-7482","authenticated-orcid":false,"given":"Kati","family":"Sarnola","sequence":"additional","affiliation":[{"name":"Research Unit Social Insurance Institution of Finland Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3672-6628","authenticated-orcid":false,"given":"Terhi","family":"Kurko","sequence":"additional","affiliation":[{"name":"Research Unit Social Insurance Institution of Finland Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201"},{"key":"e_1_2_10_3_1","unstructured":"Research and Markets \u201cJanus Kinase (JAK) Inhibitors Global Market Report 2024 \u201d2024 https:\/\/www.researchandmarkets.com\/report\/JAKinhibitor?utm_source=GNE&utm_medium=PressRelease&utm_code=cgs34q&utm_campaign=1905639+\u2010+JAK+Inhibitors+Market+Surges+as+Autoimmune+Diseases+Demand+Cutting\u2010Edge+Solutions%2c+2032F%3a+Revenues+for+Ruxolitinib%2c+Tofacitinib%2c+Oclacitinib%2c+Baricitinib%2c+Peficitinib%2c+and+Other+Inhibitor+Types&utm_exec=joca220prd."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard\u20102022\u2010223356"},{"key":"e_1_2_10_5_1","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research \u201cApplication Number: 2013214Orig1s000 Approval Letter \u201d2012 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203214Orig1s000Approv.pdf."},{"key":"e_1_2_10_6_1","unstructured":"European Medicines Agency \u201cRefusal of the Marketing Authorisation for Xeljanz (Tofacitinib) \u201d2013 https:\/\/www.ema.europa.eu\/en\/documents\/smop\u2010initial\/questions\u2010answers\u2010refusal\u2010marketing\u2010authorisation\u2010xeljanz\u2010outcome\u2010re\u2010examination_en.pdf."},{"key":"e_1_2_10_7_1","unstructured":"European Medicines Agency \u201cMeeting Highlights From the Committee for Medicinal Products for Human Use (CHMP) 23\u201326 January 2017 \u201d2017 https:\/\/www.ema.europa.eu\/en\/news\/meeting\u2010highlights\u2010committee\u2010medicinal\u2010products\u2010human\u2010use\u2010chmp\u201023\u201026\u2010january\u20102017."},{"key":"e_1_2_10_8_1","unstructured":"European Medicines Agency \u201cMeeting Highlights From the Committee for Medicinal Products for Human Use (CHMP) 12\u201315 December 2016 \u201d2016 https:\/\/www.ema.europa.eu\/en\/news\/meeting\u2010highlights\u2010committee\u2010medicinal\u2010products\u2010human\u2010use\u2010chmp\u201012\u201015\u2010december\u20102016."},{"key":"e_1_2_10_9_1","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research \u201cApplication Number: 207924Orig1s000 Other Action Letters \u201d2017 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/207924Orig1s000OtherActionLtrs.pdf."},{"key":"e_1_2_10_10_1","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research \u201cApplication Number: 207924Orig1s000 Other Action Letters \u201d2018 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/207924Orig1s000Approv.pdf."},{"key":"e_1_2_10_11_1","unstructured":"Clinicaltrials.gov \u201cSafety Study of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor in Subjects With Rheumatoid Arthritis NCT02092467 \u201d2014 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02092467."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_2_10_13_1","unstructured":"European Medicines Agency \u201cXeljanz \u201dhttps:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xeljanz."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae163.039"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13133929"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067\u2010024\u201007099\u20109"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1445680"},{"key":"e_1_2_10_18_1","unstructured":"European Medicines Agency \u201cIncreased Risk of Blood Clots in Lungs and Death With Higher Dose of Xeljanz (Tofacitinib) for Rheumatoid Arthritis \u201d2019 https:\/\/www.ema.europa.eu\/en\/news\/increased\u2010risk\u2010blood\u2010clots\u2010lungs\u2010and\u2010death\u2010higher\u2010dose\u2010xeljanz\u2010tofacitinib\u2010rheumatoid\u2010arthritis."},{"key":"e_1_2_10_19_1","unstructured":"European Medicines Agency \u201cRestrictions in Use of Xeljanz While EMA Reviews Risk of Blood Clots in Lungs \u201d2019 https:\/\/www.ema.europa.eu\/en\/news\/restrictions\u2010use\u2010xeljanz\u2010while\u2010ema\u2010reviews\u2010risk\u2010blood\u2010clots\u2010lungs."},{"key":"e_1_2_10_20_1","unstructured":"European Medicines Agency \u201cEMA Confirms Xeljanz to be Used With Caution in Patients at High Risk of Blood Clots \u201d2019 https:\/\/www.ema.europa.eu\/en\/news\/ema\u2010confirms\u2010xeljanz\u2010be\u2010used\u2010caution\u2010patients\u2010high\u2010risk\u2010blood\u2010clots."},{"key":"e_1_2_10_21_1","unstructured":"European Medicines Agency \u201cXeljanz\u2014Referral \u201d2020 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/xeljanz."},{"key":"e_1_2_10_22_1","unstructured":"European Medicines Agency \u201cXeljanz\u2014Direct Healthcare Professional Communication (DHPC) \u201d2021 https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/xeljanz."},{"key":"e_1_2_10_23_1","unstructured":"European Medicines Agency \u201cEMA Starts Safety Review of Janus Kinase Inhibitors for Inflammatory Disorders \u201d2022 https:\/\/www.ema.europa.eu\/en\/news\/ema\u2010starts\u2010safety\u2010review\u2010janus\u2010kinase\u2010inhibitors\u2010inflammatory\u2010disorders."},{"key":"e_1_2_10_24_1","unstructured":"European Medicines Agency \u201cEMA Recommends Measures to Minimise Risk of Serious Side Effects With Janus Kinase Inhibitors for Chronic Inflammatory Disorders \u201d2022 https:\/\/www.ema.europa.eu\/en\/news\/ema\u2010recommends\u2010measures\u2010minimise\u2010risk\u2010serious\u2010side\u2010effects\u2010janus\u2010kinase\u2010inhibitors\u2010chronic\u2010inflammatory\u2010disorders."},{"key":"e_1_2_10_25_1","unstructured":"European Medicines Agency \u201cCibinqo\/Jyseleca\/Olumiant\/Rinvoq\/Xeljanz\u2014Direct Healthcare Professional Communication (DHPC) \u201d2023 https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/cibinqo\u2010jyseleca\u2010olumiant\u2010rinvoq\u2010xeljanz."},{"key":"e_1_2_10_26_1","unstructured":"Data Resources Catalogue \u201cDispensed Medicines Reimbursable Under the National Health Insurance Scheme \u201daccessed April 1 2026 https:\/\/aineistokatalogi.fi\/catalog\/studies\/ff551f4e\u20106842\u20104732\u2010962d\u201074499a339c46\/datasets\/0644617c\u20100bac\u201044a8\u2010a15d\u20101724fe10e371."},{"key":"e_1_2_10_27_1","unstructured":"Findata \u201cSocial and Health Data Permit Authority \u201daccessed April 1 2026 https:\/\/findata.fi\/en\/."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00393\u2010025\u201001728\u20107"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102019\u2010216656"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjab178"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjae091"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs\u20102021\u2010013910"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.31204"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0322849"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard\u20102022\u2010223050"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70389","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.70389","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:57:57Z","timestamp":1781585877000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/pds.70389"],"URL":"https:\/\/doi.org\/10.1002\/pds.70389","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"2025-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70389"}}